Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sunrest Lifescience Ltd is a below average quality company.
The key valuation ratios of Sunrest Lifescience Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sunrest Lifescience Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 1.5% | 6.8% | 22.5% | 43.6% | - |
| Value Creation Index ⓘ | -0.9 | -0.5 | 0.6 | 2.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 11 | 17 | 26.9 | 24.6 | 25 |
| Sales YoY Gr. | - | 54.8% | 58.6% | -8.4% | - |
| Adj EPS ⓘ | 0.1 | 0.6 | 2.5 | 6.8 | 4.8 |
| YoY Gr. | - | 358.3% | 361.8% | 168.1% | - |
| BVPS (₹) ⓘ | 0.4 | 1 | 3.6 | 10.4 | 32.5 |
| Adj Net Profit ⓘ | 0 | 0.2 | 0.8 | 2 | 2 |
| Cash Flow from Ops. ⓘ | -0.9 | 0.2 | -0.5 | 1.2 | - |
| Debt/CF from Ops. ⓘ | -2.5 | 15.1 | -7.2 | 1.9 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 31% | -8.4% | ||||
| Adj EPS ⓘ | NA | NA | 284.3% | 168.1% | ||||
| BVPSⓘ | NA | NA | 189% | 190.8% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 28.4 | 78 | 111.4 | 97.6 | 22.2 |
| Op. Profit Mgn % ⓘ | 1.4 | 1.6 | 4.1 | 11.8 | NAN |
| Net Profit Mgn % ⓘ | 0.3 | 1 | 2.8 | 8.3 | 8.3 |
| Debt to Equity ⓘ | 17.5 | 7.9 | 3 | 0.7 | - |
| Working Cap Days ⓘ | 0 | 160 | 143 | 207 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 54 | 30 | 56 | 0 |
Sales growth is growing at healthy rate in last 3 years 31.04%
Net Profit is growing at healthy rate in last 3 years 284.29%
Debt to equity has declined versus last 3 years average to 0.69
Return on Equity has declined versus last 3 years average to 22.20%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 4.8 | - |
| TTM Sales (₹ Cr.) | 24.6 | - |
| BVPS (₹.) ⓘ | 32.5 | - |
| Reserves (₹ Cr.) ⓘ | 10 | - |
| P/BV ⓘ | 2.15 | - |
| PE ⓘ | 14.68 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 30 |
| Equity (₹ Cr.) | 4.3 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 77.6 |
| Pledged * | 0.00 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|
| Sales | 10.95 | 16.95 | 26.89 | 24.64 |
| Operating Expenses ⓘ | 10.80 | 16.67 | 25.78 | 21.74 |
| Manufacturing Costs | 0.07 | 0.13 | 0.11 | 0.10 |
| Material Costs | 7.39 | 11.35 | 17.46 | 14.88 |
| Employee Cost | 2.06 | 2.37 | 2.54 | 2.92 |
| Other Costs ⓘ | 1.29 | 2.82 | 5.66 | 3.85 |
| Operating Profit ⓘ | 0.15 | 0.28 | 1.11 | 2.90 |
| Operating Profit Margin (%) | 1.4% | 1.6% | 4.1% | 11.8% |
| Other Income ⓘ | 0 | 0 | 0.02 | 0.03 |
| Interest ⓘ | 0 | 0.01 | 0.02 | 0.06 |
| Depreciation ⓘ | 0.02 | 0.04 | 0.06 | 0.13 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0.14 | 0.22 | 1.05 | 2.74 |
| Tax ⓘ | 0.10 | 0.06 | 0.27 | 0.70 |
| Profit After Tax | 0.04 | 0.17 | 0.78 | 2.04 |
| PAT Margin (%) | 0.3% | 1.0% | 2.9% | 8.3% |
| Adjusted EPS (₹) | 0.1 | 0.6 | 2.6 | 6.8 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 0.13 | 0.29 | 1.07 | 3.12 | ||||||
| Share Capital ⓘ | 0.01 | 0.01 | 0.01 | 3 | ||||||
| Reserves ⓘ | 0.12 | 0.28 | 1.06 | 0.12 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 2.27 | 2.28 | 3.09 | 2 | ||||||
| Long Term Debt | 2.27 | 2.28 | 3.09 | 2 | ||||||
| Short Term Debt | 0 | 0 | 0 | 0 | ||||||
| Trade Payables | 3.54 | 6.41 | 7.93 | 8.62 | ||||||
| Others Liabilities ⓘ | 0.31 | 0.49 | 0.92 | 2.97 | ||||||
| Total Liabilities ⓘ | 6.25 | 9.47 | 13.01 | 16.70 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 0.06 | 0.22 | 0.51 | 0.53 | ||||||
| Accumulated Depreciation | 0.03 | 0.07 | 0.05 | 0.18 | ||||||
| Net Fixed Assetsⓘ | 0.03 | 0.15 | 0.47 | 0.35 | ||||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | ||||||
| Investmentsⓘ | 0 | 0 | 0 | 0.02 | ||||||
| Inventories | 0.48 | 1.52 | 2.30 | 3.94 | ||||||
| Trade Receivables | 5.37 | 7.40 | 9.35 | 10.86 | ||||||
| Cash Equivalents | 0.34 | 0.37 | 0.48 | 0.45 | ||||||
| Others Assetsⓘ | 0.03 | 0.03 | 0.43 | 1.08 | ||||||
| Total Assets ⓘ | 6.25 | 9.47 | 13.01 | 16.70 | ||||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -0.90 | 0.15 | -0.45 | 1.15 |
| PBT ⓘ | 0.14 | 0.22 | 1.05 | 2.74 |
| Adjustment ⓘ | 0.03 | 0.05 | 0.05 | 0.19 |
| Changes in Working Capital ⓘ | -1 | -0.05 | -1.47 | -1.4 |
| Tax Paid ⓘ | -0.06 | -0.07 | -0.08 | -0.38 |
| Cash Flow From Investing Activity ⓘ | -0.01 | -0.16 | -0.36 | -0.03 |
| Capex | -0.01 | -0.16 | -0.36 | -0.01 |
| Net Investments | 0 | 0 | 0 | -0.02 |
| Others ⓘ | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 1.11 | 0.04 | 0.91 | -1.15 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | -0.01 | -0.01 | -0.06 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | 1.11 | 0.05 | 0.92 | -1.10 |
| Net Cash Flow ⓘ | 0.20 | 0.03 | 0.11 | -0.03 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 28.44 | 78.01 | 113.7 | 97.59 | ||||||
| ROCE (%) | 5.72 | 9.26 | 31.03 | 58.59 | ||||||
| Asset Turnover Ratio | 1.75 | 2.16 | 2.39 | 1.66 | ||||||
| PAT to CFO Conversion(x) | -22.5 | 0.88 | -0.58 | 0.56 | Working Capital Days | |||||
| Receivable Days | 179 | 138 | 114 | 150 | ||||||
| Inventory Days | 16 | 22 | 26 | 46 | ||||||
| Payable Days | 175 | 160 | 150 | 203 | ||||||
Sunrest Lifescience was originally incorporated as ‘Sunrest Lifescience Private Limited’ as a Private Limited Company under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated October 30, 2017, issued by the Registrar of Companies, Ahmedabad, Gujarat. Subsequently, the company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of the company held on March 09, 2023 and the name of the company was changed to ‘Sunrest Lifescience Limited’. A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company was issued by the Registrar of Companies, Ahmedabad on March 21, 2023.
The company is engaged in the marketing of OTC generic pharmaceutical products in the domestic market. The company offer range of pharmaceutical products manufactured by third party manufacturers. The company operates in different States of India such as Maharashtra, Gujarat, Madhya Pradesh, Orissa and Rajasthan. The company have presence in these States through Trade Mark registered products and/or products under registration. It deals in Capsules, Tablets, Syrup, Ointment, Gel, Mouth Wash, Solution, Suspension, Dry Powders and Toothpaste.
Its product portfolio comprises of vide range of drugs like Anti-Bacterial, Anti Diarrheal, AntiFungal, Anti Malerial, Anti Diabetic, Dental Cure, Anti Protozol, Anti Histamine, Anti-Hypertensive drugs, Cosmetic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical and Anti-inflammatory. The company has 18 Registered Trademarks for 32 products. The products of the Company are sold to Stockists and Super Stockists & in turn it is available at Chemist shops, Dispensaries, Hospitals etc. Its business operations are supported by one of its Group Company and various third-party manufacturers. It typically works on third-party manufacturing basis or at times purchase order basis with manufacturer of pharma products, depending upon customer’s requirement.
Business area of the company
The company is engaged in the business of marketing and distribution of pharmaceutical products in the domestic market. The company offers wide range of pharmaceutical formulations and products manufactured by third party manufacturers.
Products of the company
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
